Calidi Biotherapeutics, Inc.
Symbol: CLDI (NYSE)
1.55
▼ (-3.19%) -0.051
Company Description:
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
Key Stats
- Today's Open: $1.58
- Today's High: $1.604
- Today's Low: $1.545
- Today's Volume: 21.75K
- Yesterday Close: $1.6
- Yesterday High: $1.62
- Yesterday Low: $1.58
- Yesterday Volume: 52.87K
- Last Min Volume: 92
- Last Min High: $1.549
- Last Min Low: $1.546
- Last Min VWAP: $1.54604
Company Profile
- Name: Calidi Biotherapeutics, Inc.
- Website: https://www.calidibio.com
- Listed Date: 2023-09-13
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001855485
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $8.56M
- Round Lot: 100
- Outstanding Shares: 5.35M
- Asset Type: CS
RECENT FILINGS FOR CLDI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-19 | 8-K | View |
| 2025-09-05 | 4 | View |
| 2025-09-05 | 4 | View |
| 2025-09-05 | 4 | View |
| 2025-08-29 | 8-K | View |
| 2025-08-27 | SCHEDULE 13G | View |
| 2025-08-27 | 3 | View |
| 2025-08-25 | 4 | View |
| 2025-08-25 | 4 | View |
| 2025-08-25 | 4 | View |
| 2025-08-25 | 4 | View |
| 2025-08-22 | 8-K | View |
| 2025-08-21 | 424B4 | View |
| 2025-08-20 | EFFECT | View |
| 2025-08-19 | CORRESP | View |
| 2025-08-19 | CORRESP | View |
| 2025-08-15 | S-1 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 8-K | View |
| 2025-08-08 | 10-Q | View |
Latest News on CLDI